Desh Rakshak Aushdhalaya Limited Stock Price Today (NSE: DESHRAK)
Fundamental Score
Desh Rakshak Aushdhalaya Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Desh Rakshak Aushdhalaya Limited share price today is ₹31.00, up +0.00% on NSE/BSE as of 3 August 2026. Desh Rakshak Aushdhalaya Limited (DESHRAK) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹17.66 (Cr). The 52-week high for DESHRAK share price is ₹95.14 and the 52-week low is ₹22.45. At a P/E ratio of 31.54x, DESHRAK is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 4.82% and a debt-to-equity ratio of 0.21.
Desh Rakshak Aushdhalaya Limited Share Price Chart — NSE/BSE Historical Performance
Desh Rakshak Aushdhalaya Limited share price chart: -9.62% return over the past month. 52-week high ₹95.14, 52-week low ₹22.45.
Desh Rakshak Aushdhalaya Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹31.00 | ₹31.00 | ₹31.00 | ₹31.00 | 0.00 (Cr) | |
| ₹31.00 | ₹31.00 | ₹31.00 | ₹31.00 | 0.00 (Cr) | |
| ₹31.00 | ₹31.00 | ₹31.00 | ₹31.00 | 0.00 (Cr) | |
| ₹31.00 | ₹31.00 | ₹31.00 | ₹31.00 | 0.00 (Cr) | |
| ₹31.00 | ₹31.00 | ₹31.00 | ₹31.00 | 0.00 (Cr) | |
| ₹31.00 | ₹31.00 | ₹31.00 | ₹31.00 | 0.00 (Cr) | |
| ₹31.00 | ₹31.00 | ₹31.00 | ₹31.00 | 0.00 (Cr) | |
| ₹31.00 | ₹31.00 | ₹31.00 | ₹31.00 | 0.00 (Cr) | |
| ₹31.00 | ₹31.00 | ₹31.00 | ₹31.00 | 0.00 (Cr) | |
| ₹31.00 | ₹31.00 | ₹31.00 | ₹31.00 | 100.00 (Cr) |
Desh Rakshak Aushdhalaya Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹34.30 | ₹34.30 | ₹30.97 | ₹31.00 | -9.62% | |
| ₹35.00 | ₹35.00 | ₹34.30 | ₹34.30 | -2.00% | |
| ₹23.62 | ₹38.43 | ₹22.45 | ₹35.00 | +48.18% | |
| ₹27.00 | ₹27.00 | ₹22.50 | ₹23.62 | -12.52% | |
| ₹24.37 | ₹28.03 | ₹23.16 | ₹27.00 | +10.79% | |
| ₹32.00 | ₹32.00 | ₹24.37 | ₹24.37 | -23.84% | |
| ₹32.00 | ₹32.00 | ₹32.00 | ₹32.00 | +0.00% | |
| ₹37.00 | ₹37.00 | ₹30.49 | ₹32.00 | -13.51% | |
| ₹39.54 | ₹47.57 | ₹30.62 | ₹37.00 | -6.42% | |
| ₹62.68 | ₹62.68 | ₹41.62 | ₹41.62 | -33.60% | |
| ₹82.62 | ₹82.62 | ₹62.68 | ₹62.68 | -24.13% | |
| ₹95.14 | ₹95.14 | ₹82.62 | ₹82.62 | -13.16% |
AI Research Briefing
Powered by Gemini · 2026-08-01
Sub-scale ayurvedic micro-cap with negative 5-year free cash flow and dismal 4.82% ROE, functioning purely as a low-liquidity trading shell.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major news or order catalysts found in the last 2-4 weeks. Recent corporate actions include executing a tripartite agreement to transition its Registrar and Share Transfer Agent (RTA) to Nivis Corpserve LLP effective June 17, 2026. Financial performance shows full-year FY26 revenue of ₹7.10 Cr (up from ₹6.27 Cr in FY25) with net profit growing 18% to ₹0.56 Cr. However, the latest quarterly run rate shows severe contraction, with quarterly sales down 21.41% YoY and profit falling 16.67% YoY.
CORE STORY (THE REAL GAME)
This is an illiquid micro-cap legacy ayurvedic medicine manufacturer operating at a tiny sub-scale level. Despite a century-old brand origin in Haridwar, the core game is an illiquid nano-cap trading vehicle with zero institutional coverage and minimal organic volume. Management raised ₹2.77 Cr via a preferential allotment at ₹22 per share to meet basic working capital needs rather than scale production.
- No major catalysts or fresh order wins found in live search over the past 4 weeks.
- Latest quarterly sales plunged 21.41% YoY, highlighting core operational weakness.
- Transitioned RTA agent to Nivis Corpserve LLP in June 2026 following ₹2.77 Cr preferential equity dilution.
- Potential SME takeover or reverse merger spec.
- B2B distribution expansion or government AYUSH contract wins.
- Sudden micro-cap volume spike on low floating stock.
- Severe liquidity risk due to micro-cap status (₹17.66 Cr market cap) and negligible trading volume.
- Negative 5-year Free Cash Flow of ₹-3.42 Cr despite reported GAAP profits.
- Abysmal capital efficiency with ROE at 4.82% and 5-year sales CAGR at 1.59%.
Zero FII and DII holdings (0.0% participation). Promoter stake flat at 50.03% with zero pledges.
India's pharma sector is benefiting from government API and AYUSH pushes, but tiny regional players lack the scale to capture market share.
No major news found after live search; raised ₹2.77 Cr via preferential allotment in FY26 purely for working capital.
Poor cash quality; net profit of ₹0.56 Cr in FY26 fails to generate real cash, leading to 5Y FCF of ₹-3.42 Cr.
Sub-par growth and weak quarterly trajectory point to continued underperformance. Avoid until cash flows turn positive.
Primary Thesis Risk
Complete liquidity lockup combined with severe operational contraction destroying capital.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Desh Rakshak Aushdhalaya Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Desh Rakshak Aushdhalaya Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of DESHRAK across key market metrics for learning purposes.
Positive Indicators
4 factors identified
Strong Operating Margins (20.70%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Conservative Debt Levels (D/E: 0.21)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Balanced Promoter Holding (50.03%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
8 factors identified
Below-Average Return on Equity (4.82%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (6.53%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-16.67%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-21.41%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Growth History (1.59% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (0.76% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Negative Free Cash Flow (₹-3.42 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Desh Rakshak Aushdhalaya Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Desh Rakshak Aushdhalaya Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Desh Rakshak Aushdhalaya LimitedDesh Rakshak Au...Selected✓ DESHRAK • 531521 | 24.4/100 | ₹31.00₹31 | ₹17.66₹17.66 | 31.54Average 31.5 Average | 4.82%Poor 4.82% Poor | 6.53%Poor 6.53% Poor | 0.21Excellent 0.2 Excellent | 5.92%Good 5.92% Good | 1.59%Average 1.59% Average | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Desh Rakshak Aushdhalaya Limited PE Ratio History
Historical price-to-earnings ratio for DESHRAK — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹0.96 | ₹16.57 | 17.3x |
| FY 2023 | ₹0.14 | ₹6.31 | 46.7x |
| FY 2022 | ₹1.08 | ₹4.96 | 4.6x |
| FY 2021 | ₹0.95 | ₹4.10 | 4.3x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Desh Rakshak Aushdhalaya Limited Quarterly Performance
Latest quarterly metrics for DESHRAK — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-21.41%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-16.67%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
1.59%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
5.92%
Compounded annual net profit growth over 5 years
Desh Rakshak Aushdhalaya Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for DESHRAK — calculated from daily price history
Selling pressure is heavy — potential reversal zone.
Technical indicators are for educational purposes only. Not investment advice.
Desh Rakshak Aushdhalaya Limited Financial Statements
Annual income statement, balance sheet and cash flow for Desh Rakshak Aushdhalaya Limited (DESHRAK) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Desh Rakshak Aushdhalaya Limited
About DESHRAK (Desh Rakshak Aushdhalaya Limited)
Desh Rakshak Aushdhalaya Limited is a venerable institution deeply rooted in India's rich heritage of Ayurveda. For over a century, DESHRAK has been dedicated to crafting authentic... and effective remedies drawing upon time-tested formulations and natural ingredients. Nestled in the serene landscapes of Haridwar, the company meticulously blends ancient wisdom with modern manufacturing practices to produce a diverse portfolio of health and wellness solutions. From single-ingredient preparations to complex, multi-herb combinations, DESHRAK strives to offer holistic support for various health concerns, empowering individuals to embrace a balanced and healthy lifestyle. The company's commitment to quality and efficacy extends to every stage of production, from sourcing raw materials to rigorous testing, ensuring that each product reflects the purity and potency of nature's healing power. DESHRAK's product range encompasses a wide spectrum of Ayurvedic medicines designed to promote overall well-being and address specific health needs. These include traditional tablets, easily digestible capsules, and palatable syrups, alongside classic powders and concentrated liquid extracts. A particular strength of DESHRAK lies in its specialized Ayurvedic kits, thoughtfully curated collections of synergistic herbs designed to target particular health issues or support specific life stages. These kits, along with herbal dye solutions and community health worker (CHW) kits, exemplify the company's innovative approach to delivering comprehensive healthcare solutions, making the benefits of Ayurveda accessible to a broader population. The company prides itself on maintaining traditional methods and quality in the manufacturing of these products. With a steadfast dedication to its founding principles, DESHRAK not only serves the domestic market but also extends its reach globally through its export operations. This commitment enables DESHRAK to share the healing potential of Ayurveda with individuals worldwide, contributing to a growing appreciation for natural and holistic approaches to health. The legacy of DESHRAK is built upon a foundation of integrity, innovation, and a deep respect for the traditions of Ayurveda. As a trusted name in the pharmaceutical landscape, DESHRAK remains committed to providing high-quality, safe, and effective Ayurvedic solutions that empower individuals to live healthier, more fulfilling lives.
Company Details
Key Leadership
DESHRAK Share Price: Frequently Asked Questions
What is the current share price of Desh Rakshak Aushdhalaya Limited?
Desh Rakshak Aushdhalaya Limited (DESHRAK) trades at ₹31.00 on NSE and BSE. Market cap ₹17.66 (Cr). Educational data only.
What is the P/E ratio of Desh Rakshak Aushdhalaya Limited?
Desh Rakshak Aushdhalaya Limited has a P/E of 31.54x vs industry average 34.89x.
What is the Bull Run score for Desh Rakshak Aushdhalaya Limited?
Desh Rakshak Aushdhalaya Limited has a Bull Run score of 24.4/100 based on 25+ financial parameters.
Does Desh Rakshak Aushdhalaya Limited pay dividends?
Desh Rakshak Aushdhalaya Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Desh Rakshak Aushdhalaya Limited?
Desh Rakshak Aushdhalaya Limited has ROE of 4.82%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Desh Rakshak Aushdhalaya Limited?
Desh Rakshak Aushdhalaya Limited has debt-to-equity of 0.21.
Is Desh Rakshak Aushdhalaya Limited a good investment?
Bull Run gives Desh Rakshak Aushdhalaya Limited a score of 24.4/100. This is not investment advice — consult a SEBI-registered advisor.